Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance.

Blood·2025

Same author

Platelet Pathophysiology: Unexpected New Research Directions.

Seminars in thrombosis and hemostasis·2024

Same author

Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome.

Scientific reports·2024

Same author

Platelet Physiology.

Seminars in thrombosis and hemostasis·2024

Same author

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.

Blood·2022

Same author

Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia.

Immunity·2022

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: May 26, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Advances in antiplatelet therapy.

Alan D Michelson¹

¹Center for Platelet Research Studies, Division of Hematology/Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-5737, USA. alan.michelson@childrens.harvard.edu

Hematology. American Society of Hematology. Education Program

|December 14, 2011

Summary

This summary is machine-generated.

New antiplatelet therapies, including novel P2Y(12) antagonists, show promise for treating cardiovascular atherothrombosis. Ongoing studies assess their efficacy and safety compared to existing treatments like clopidogrel.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 26, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

Cardiovascular Medicine
Pharmacology
Hematology

Background:

Platelets play a key role in cardiovascular atherothrombosis.
Current antiplatelet therapies like aspirin and clopidogrel have limitations, with a significant incidence of arterial thrombosis persisting.
Existing treatments include cyclooxygenase 1 (COX1) inhibitors, P2Y(12) receptor antagonists, and GPIIb-GPIIIa antagonists.

Purpose of the Study:

To review the role of antiplatelet therapy in cardiovascular atherothrombosis.
To discuss novel antiplatelet agents and their potential advantages over existing therapies.
To highlight ongoing research and clinical trials for new antithrombotic agents.

Main Methods:

Review of current antiplatelet therapies.
Discussion of novel P2Y(12) antagonists (prasugrel, ticagrelor, cangrelor, elinogrel) and their mechanisms.
Overview of ongoing phase 3 trials for new antiplatelet agents, including PAR1 antagonists.

Main Results:

Novel P2Y(12) antagonists offer more rapid, consistent, and complete platelet inhibition compared to clopidogrel.
Phase 3 studies are evaluating the clinical benefits and safety profiles of these new agents.
Emerging agents targeting protease-activated receptor 1 (PAR1) are also under investigation.

Conclusions:

Despite established antiplatelet therapies, significant rates of arterial thrombosis persist.
Newer P2Y(12) antagonists demonstrate improved platelet inhibition, with ongoing trials to confirm clinical outcomes and safety.
Further research into novel antiplatelet agents, including PAR1 antagonists, is crucial for advancing atherothrombosis treatment.